Mednet Logo
HomeMedical Oncology
Medical Oncology

Medical Oncology

Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.

Recent Discussions

Do you diagnose MCAS if a patient is concurrently on drugs known to cause non-specific mast cell degranulation?

1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Brigham And Womens Hospital Respiratory Immunology Lab

Yes, MCAS may be diagnosed if a patient is on drugs known to cause non-specific mast cell activation.The reason for this answer requires a better understanding of MCAS criteria and etiology. In 2022, an expert consortium proposed revisions to the classification of mast cell activation disorders. (Va...

How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?

2
3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Rochester

As a pediatric hematologist/oncologist and pediatric palliative care physician, I can only speak to our approach with children, which may be quite different than the adult world. In our community, we are not able to provide blood or platelet transfusions in the home. For children who are profoundly ...

How do you manage patients desiring home hospice but with severe thrombocytopenia and/or anemia due to advanced malignancy?

2
3 Answers

Mednet Member
Mednet Member
Pediatric Hematology/Oncology · University of Rochester

As a pediatric hematologist/oncologist and pediatric palliative care physician, I can only speak to our approach with children, which may be quite different than the adult world. In our community, we are not able to provide blood or platelet transfusions in the home. For children who are profoundly ...

What are your top takeaways from ASCO GU 2025?

3
6 Answers

Mednet Member
Mednet Member
Medical Oncology · Duke University School of Medicine

In terms of practice-informing presentations in prostate cancer here are my top 3: GROUQ-PCS 9 trial (Canada, abstract 22). This trial led by Niazi et al tested whether metastasis-directed radiotherapy based on conventional imaging to up to 5 sites provided benefits in delaying rPFS or PSA progressi...

In which patients do you utilize a breast MRI as part of the initial workup for breast cancer?

5
4 Answers

Mednet Member
Mednet Member
Radiation Oncology · University of Arkansas for Medical Sciences

I'm not a fan of routine MRI in the work-up for early-stage breast cancer, but I do agree with the fairly standard list of selective indications mentioned previously. I also obtain an MRI when there is a significant discrepancy between standard imaging and physical exam. Examples would be: One or a...

For a patient with ICI toxicity who is resistant to the use of high-dose steroids, are there scenarios where you would consider the use of first-line conventional synthetic DMARD in place of steroids?

2
2 Answers

Mednet Member
Mednet Member
Rheumatology · Ohio State University

Loaded question — I think we need a reframing of ICI-toxicity, much of the ICI side effects are just an autoimmune reaction in a specific organ. High doses of steroids are used if there is a true risk for organ damage (like when you have acute ANCA vasculitis, lupus nephritis, etc.). So if a patient...

Would you ever consider adjuvant chemotherapy for a patient with rectal cancer treated with RAPIDO total neoadjuvant therapy after positive PNI was found on the surgery?

1
1 Answers

Mednet Member
Mednet Member
Medical Oncology · Kettering Cancer Care

The patient should have received adequate systemic therapy per the RAPIDO trial; therefore, additional chemotherapy will not add any further benefit.

Does delay to the time of lumpectomy impact your decision to omit radiation?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Beth Israel Deaconess Medical Center

There seem to be two issues to consider in this situation. One is whether patients undergoing neoadjuvant endocrine therapy, then lumpectomy without RT, have an acceptable local recurrence rate. The only study I know of directly addressing this issue was presented at a poster session of the 2017 San...

What are your top takeaways in Neuro Oncology from ASCO 2025?

1
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Mayo Clinic

Aizer et al., JCO 2025 - A multi-instituitional Brigham Dana-Farber-led trial randomized 196 patients with 5-20 brain metastases to stereotactic radiosurgery (SRS) or hippocampal avoidance whole brain radiotherapy (HA-WBRT). Patients treated on the SRS arm had significantly less symptom burden, wit...

How would you treat node positive (pN+) prostate cancer with undetectable post-op PSA after radical prostatectomy and pelvic LND?

9
5 Answers

Mednet Member
Mednet Member
Radiation Oncology · Case Western Reserve University/ University Hospitals Seidman Cancer Center

The short answer is, YES I would, in general, recommend treatment. I also respectfully disagree that ADT monotherapy is the standard of care. It is an option of course, but rarely performed given it is non-curative and the data to support its use is of minimal relevance today.Some key points of reas...